Denali Therapeutics Inc.
NEWS
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer’s Drug
Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
In a paper published on Wednesday, Denali detailed the engineering of its transport vehicles.
April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.
We thought it would be insightful to look back at our previous lists to see where some of those companies are today. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2017.
Researchers at the University of California, San Diego (UCSD) ran successful animal studies of a gene therapy that appeared to cure a disease in mice similar to amyotrophic lateral sclerosis (ALS), sometimes also known as Lou Gehrig’s Disease.
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
JOBS
IN THE PRESS